Pneumococcal polyarticular septic arthritis after a single infusion of infliximab in a rheumatoid arthritis patient: A case report

被引:1
作者
Masatoshi Hayashi
Toshihisa Kojima
Koji Funahashi
Daizo Kato
Hiroyuki Matsubara
Tomone Shioura
Yasuhide Kanayama
Yuji Hirano
Masao Deguchi
Toshihisa Kanamono
Naoki Ishiguro
机构
[1] Departments of Orthopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, 380-8582
[2] Departments of Orthopedic Surgery and Rheumatology, Nagoya University, Graduate School of Medicine, Showa-ku, Nagoya, 466-8550
[3] Department of Orthopedic Surgery, Shizuoka Kosei Hospital, Aoi-ku, Shizuoka, 420-8623
[4] Department of Orthopedic Surgery, Nagoya Kyoritsu Hospital, Nakagawa-ku, Nagoya, 454-0933
[5] Departments of Orthopedic Surgery and Rheumatology, Toyohashi Municipal Hospital, Aotake-cho, Toyohashi, 441-8570
关键词
infliximab; rheumatoid arthritis; septic arthritis; Streptococcus pneumoniae;
D O I
10.1186/1752-1947-6-81
中图分类号
学科分类号
摘要
Abstract. Introduction. We present a case of Streptococcus pneumoniae polyarticular septic arthritis in a patient with rheumatoid arthritis receiving a single infusion of infliximab. Case presentation. A 38-year-old Japanese man with a 5-year history of seronegative rheumatoid arthritis had previously received sulphasalazine and methotrexate therapies and was on regular low-dose prednisolone therapy. Despite these treatments, his disease activity remained high and infliximab was introduced in addition to methotrexate, prednisolone, and folic acid. However, he was admitted to hospital with a fever of 40.6°C, chills, and polyarthralgia eight days after the first infusion of infliximab. His joints were swollen, painful, and warm. Laboratory data showed marked acute inflammation. He was diagnosed with bacterial septic polyarthritis, and emergency surgical joint lavage and drainage was performed at the knees along with needle aspiration and lavage of the ankles and right wrist. He was then given intravenous antibiotic therapy for 31 days. He made a good recovery and was discharged on day 37. Conclusions: We believe this is the first reported case of severe pneumococcal septic arthritis requiring hospitalization in a patient treated with infliximab. S. pneumonia is now a well-recognized but uncommon cause of polyarticular septic arthritis that can lead to cessation of therapy, as in our patient's case. © 2012 Hayashi et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 19 条
[1]  
Paulos C.M., Turk M.J., Breur G.J., Low P.S., Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis, Advanced Drug Delivery Reviews, 56, 8, pp. 1205-1217, (2004)
[2]  
Taylor P.C., Feldmann M., Anti-TNF biologic agents: Still the therapy of choice for rheumatoid arthritis, Nat Rev Rheumatol, 5, pp. 578-582, (2009)
[3]  
Lohse A., Despaux J., Auge B., Toussirot E., Wendling D., Pneumococcal polyarticular septic arthritis in a patient with rheumatoid arthritis, Rev Rhum Engl Ed, 66, pp. 344-346, (1999)
[4]  
Yamanaka H., Tanaka Y., Sekiguchi N., Inoue E., Saito K., Kameda H., Iikuni N., Nawata M., Amano K., Shinozaki M., Takeuchi T., Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM), Modern Rheumatology, 17, 1, pp. 28-32, (2007)
[5]  
Listing J., Strangfeld A., Kary S., Rau R., Von Hinueber U., Stoyanova-Scholz M., Gromnica-Ihle E., Antoni C., Herzer P., Kekow J., Schneider M., Zink A., Infections in patients with rheumatoid arthritis treated with biologic agents, Arthritis and Rheumatism, 52, 11, pp. 3403-3412, (2005)
[6]  
Westhovens R., Yocum D., Han J., Berman A., Strusberg I., Geusens P., Rahman M.U., The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial, Arthritis and Rheumatism, 54, 4, pp. 1075-1086, (2006)
[7]  
Takeuchi T., Tatsuki Y., Nogami Y., Ishiguro N., Tanaka Y., Yamanaka H., Kamatani N., Harigai M., Ryu J., Inoue K., Kondo H., Inokuma S., Ochi T., Koike T., Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, 67, 2, pp. 189-194, (2008)
[8]  
Doran M.F., Crowson C.S., Pond G.R., O'Fallon W.M., Gabriel S.E., Predictors of infection in rheumatoid arthritis, Arthritis Rheum, 46, pp. 2294-2300, (2002)
[9]  
Rosenblum H., Amital H., Anti-TNF therapy: Safety aspects of taking the risk, Autoimmun Rev, 10, pp. 563-568, (2011)
[10]  
Dixon W.G., Watson K., Lunt M., Hyrich K.L., Silman A.J., Symmons D.P.M., Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register, Arthritis and Rheumatism, 54, 8, pp. 2368-2376, (2006)